Grok 4 just set the bar now the smartest AI model in the world.https://t.co/BgNNqI86z4 ...

AI-powered search engines remove the need for people to trawl the web. As they take readers away, the incentive for content to be created is removed. The technology that is opening up the web also threatens to kill it https://t.co/tPAg1b0MfE ...

Taiwan Semiconductor Manufacturing Co TSM stock traded lower Friday after its Thursday gains following upbeat quarterly results.CFO Wendell Huang told Bloomberg that the contract chipmaker plans to stay cautious with spending in 2025 while accelerating global expansion to meet booming AI chip demand.The company may invest up to $42 billion in capex this year, but is closely watching macro and foreign exchange risks, especially sharp currency swings that threaten margins.Also Read: Taiwan Semiconductor’s Top ...

Meta reportedly continued its artificial intelligence (AI)-focused hiring spree by adding two AI researchers who had worked for Apple.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.The company hired Mark Lee and T ...

The Pioneer Of Seeking Alpha's BAD BEAT Investing, Quad 7 Capital is a team of 7 analysts with a wide range of experience sharing investment opportunities for nearly 12 years. They are best known for their February 2020 call to sell everything & go short, & have been on average 95% long 5% short since May 2020. The broader company has expertise in business, policy, economics, mathematics, game theory, & the sciences. They share both long & short trades & invest personally in equities they discuss within the ...

Key Takeaways Strategic acquisitions like LifeSync and CIT bolster APH's positioning in high-reliability sectors. The Andrew acquisition raised the FY accretion forecast from 6 cents to 9 cents per share. Stock is trending above its 50 and 200-day SMAs, reinforcing a bullish outlook ahead of earnings.Amphenol (APH) is set to report its second-quarter 2025 results on July 23.The company expects second-quarter 2025 earnings between 64 cents and 66 cents per share, indicating growth of 45% and 50% year over ...

5 ChatGPT Prompts To Delegate Your Work To AI And Hit The Beach https://t.co/lUlXufJyGz https://t.co/lUlXufJyGz ...

RT Chyan | chyan.base.eth (@Chyan)Smart money didn’t miss it this time — $BONK is the $HYPE rerun and they’re all in. 📈📢+157% in 30D to 11.8B bags on @nansen_ai — Bonk Guy called it, and big brains heeded this time.Missed @theunipcs #USELESS shout at the bottom. Glad I heard the bark on $BONK. 🧠🐶 https://t.co/vbDcejsC2N ...

RT BSCN (@BSCNews)AI PROTOCOL TO WATCH: THEORIQ - @TheoriqAI's Agent Swarm technology is at the forefront of CryptoAI innovation. Here's a full analysis https://t.co/MLS6YsuDxW ...

Core Viewpoint - Tevogen Bio Holdings Inc. has announced the publication of its international patent application for a machine learning-based technology aimed at identifying immunologically active peptides, which is crucial for developing targeted therapies for diseases like cancer and infections [1][2]. Group 1: Technology and Innovation - The patented technology utilizes machine learning algorithms, developed in collaboration with Microsoft and Databricks, to enhance the identification of peptides that interact strongly with the immune system [1]. - Traditional methods for identifying these peptides often overlook important genetic diversity factors, but Tevogen.AI's approach aims to address these limitations [2]. - The technology focuses on efficiently screening and ranking potential peptides based on their immunological activity and continuously refining predictions using real-world data [6]. Group 2: Strategic Goals - The company emphasizes the importance of leveraging artificial intelligence to accelerate discovery, shorten development timelines, and reduce costs in the context of personalized T cell therapies [2]. - The goal is to deliver commercially attractive and economically viable therapies for various diseases, including cancers and infectious diseases [2].